Olga Minaeva

Olga Minaeva

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2019 in Polymers
Verified
Journal Article
Open access
PDF file
MNMarina Novoselova
Marina Novoselova
SGSergei German
Sergei German
Olga SindeevaOlga Sindeeva
Olga Sindeeva
OKOleg Alexandrovich Kulikov
Oleg Alexandrovich Kulikov
OMOlga Minaeva
Olga Minaeva
Dmitry GorinDmitry Gorin
Dmitry Gorin
Although new drug delivery systems have been intensely developed in the past decade, no significant increase in the efficiency of drug delivery by nanostructure carriers has been achieved. The reasons are the lack of information about acute toxicity, the influence of the submicron size of the carrier and difficulties with the study of biodistribution in vivo. Here we propose, for the first time in vivo, new nanocomposite submicron carriers made of bovine serum albumin (BSA) and tannic acid (TA) and containing magnetite nanoparticles with sufficient content for navigation in a magnetic field gradient on mice. We examined the efficacy of these submicron carriers as a delivery vehicle in combination with magnetite nanoparticles which were systemically administered intravenously. In addition, the systemic toxicity of this carrier for intravenous administration was explicitly studied. The results showed that (BSA/TA) carriers in the given doses were hemocompatible and didn’t cause any adverse effect on the respiratory system, kidney or liver functions. A combination of gradient-magnetic-field controllable biodistribution of submicron carriers with fluorescence tomography/MRI imaging in vivo provides a new opportunity to improve drug delivery efficiency.

25 January 2017 in Journal of Physics: Conference Series
Verified
Conference Paper
Open access
PDF file
OMOlga Minaeva
Olga Minaeva
EBE P Brodovskaya
E P Brodovskaya
MPM A Pyataev
M A Pyataev
MGM V Gerasimov
M V Gerasimov
MZM N Zharkov
M N Zharkov
GSG B Sukhorukov
G B Sukhorukov

25 May 2019 in Polymers
Verified
Journal Article
Open access
PDF file
NPNikolay Pyataev
Nikolay Pyataev
PPPavel Petrov
Pavel Petrov
OMOlga Minaeva
Olga Minaeva
MZMikhail N. Zharkov
Mikhail N. Zharkov
OKOleg Alexandrovich Kulikov
Oleg Alexandrovich Kulikov
LBLarisa A. Balykova
Larisa A. Balykova
This study looked into the synthesis and study of Dextrane Sulfate–Doxorubicin Nanoparticles (DS–Dox NP) that are sensitive to amylase and show anticoagulant properties. The particles were obtained by the method of solvent replacement. They had a size of 305 ± 58 nm, with a mass ratio of DS:Dox = 3.3:1. On heating to 37 °C, the release of Dox from the particles was equal to 24.2% of the drug contained. In the presence of amylase, this ratio had increased to 42.1%. The study of the biological activity of the particles included an assessment of the cytotoxicity and the effect on hemostasis and antitumor activity. In a study of cytotoxicity on the L929 cell culture, it was found that the synthesized particles had less toxicity, compared to free doxorubicin. However, in the presence of amylase, their cytotoxicity was higher than the traditional forms of the drug. In a study of the effect of DS–Dox NP on hemostasis, it was found that the particles had a heparin-like anticoagulant effect. Antitumor activity was studied on the model of ascitic Zaidel hepatoma in rats. The frequency of complete cure in animals treated with the DS–Dox nanoparticles was higher, compared to animals receiving the traditional form of the drug.

22 February 2018 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
ASAlexander V. Semenov
Alexander V. Semenov
OBOlga I. Balakireva
Olga I. Balakireva
ITIrina V. Tarasova
Irina V. Tarasova
ABAlexey A. Burtasov
Alexey A. Burtasov
ESElena V. Semenova
Elena V. Semenova
NPNicolay A. Pyataev
Nicolay A. Pyataev

26 June 2019 in Research Results in Pharmacology
Verified
Journal Article
Open access
PDF file
OKOleg A. Kulikov
Oleg A. Kulikov
VAValentin P. Ageev
Valentin P. Ageev
EMElena E. Marochkina
Elena E. Marochkina
IDIrina S. Dolgacheva
Irina S. Dolgacheva
OMOlga Minaeva
Olga Minaeva
VIVera I. Inchina
Vera I. Inchina
Introduction: Hypertonic sodium chloride solutions and liposomal drugs with pulmotropic effect are of great interest for the treatment of acute lung injury (ALI). The results of the studies on the efficacy of hypertonic solutions and lipo[1]somes in ALI treatment are currently controversial. Materials and methods: For the experiment, liposomes with dexamethasone, N-acetylcysteine (NAC), aprotinin and dye Cyanine-7 (Cy-7) were obtained. A liposome analysis was performed by means of spectrophotometry. ALI was modeled in rats by the administration of the damaging agents into the trachea. The experimental agents were injected once intravenously after the modeling of ALI. For experimental therapy used liposomal agents, 7.5% hypertonic saline (HS) and HyperHAES solutions in the respective groups. The efficacy of the therapy was assessed by the survival of animals, functional indicators of the cardiovascular and respiratory systems, and by the lung-body ratio. The biodistri[1]bution of liposomes after intravenous administration was investigated in mice through using a fluorescent dye Cy-7. The biodistribution of liposomes with Cy-7 was assessed using bioimaging according to the fluorescence intensity of internal organs (lungs, liver, and kidneys) and blood, expressed as dye concentration according to the calibration de[1]pendence of dye concentrarion on fluorescence intensity. Results and discussion: All the studied liposomal drugs were effective for the pharmacological correction of ALI. Hypertonic solutions, unlike liposomal drugs, were less likely to prevent the development of pulmonary edema. All the studied therapeutic agents increased the survival rate of the laboratory animals with ALI. The most effective experimen[1]tal agent was liposomal dexamethasone. The use of drugs in form of simple liposomes with average diameter of 350 nm provided for a higher concentration of the drug in the lungs within the first 40 minutes after intravenous administration. Conclusion: Intravenous administration of liposomal forms is promising for the pharmacotherapy of acute lung injury.

30 March 2017 in Mordovia University Bulletin
Verified
Journal Article
Open access
YDYevdokimov Moscow State University of Medicine and Dentistry
Yevdokimov Moscow State University of Medicine and Dentistry
AZAndrey Vladimirovich Zaborovsky
Andrey Vladimirovich Zaborovsky
AKAleksandr V. Kokorev
Aleksandr V. Kokorev
OUObninsk Branch of National Research Nuclear University
Obninsk Branch of National Research Nuclear University
YBYekaterina P. Brodovskaya
Yekaterina P. Brodovskaya
VMVyacheslav Yu. Medvezhonkov
Vyacheslav Yu. Medvezhonkov
Официальный сайт журнала "Вестник Мордовского университета"